{"id":7511,"date":"2025-10-06T10:29:20","date_gmt":"2025-10-06T06:29:20","guid":{"rendered":"https:\/\/medscriptum.org\/?p=7511"},"modified":"2025-10-06T10:33:06","modified_gmt":"2025-10-06T06:33:06","slug":"study-weight-loss-medications-reduce-alcohol-dependence","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/study-weight-loss-medications-reduce-alcohol-dependence\/","title":{"rendered":"Study: Weight Loss Medications Reduce Alcohol Dependence"},"content":{"rendered":"<div class=\"ng-tns-c256135399-48\">\n<section id=\"processing-state-2\" class=\"processing-state_container ng-tns-c256135399-48 is-gpi-avatar ng-trigger ng-trigger-processingStateShowHide ng-star-inserted is-done-processing\">\n<div id=\"processing-state-2-summary\" class=\"processing-state_details ng-trigger ng-trigger-menuExpansion ng-tns-c256135399-48 is-gpi-avatar ng-star-inserted\" aria-hidden=\"true\">A recent, large-scale genetic study has revealed significant potential: medications already used to treat <b>Type 2 Diabetes<\/b> and <b>obesity<\/b> may also be effective in <b>reducing alcohol consumption<\/b> and, consequently, <b>improving liver function<\/b>. This research, published in the journal <i>Molecular Psychiatry<\/i>, points to the possibility of developing entirely new pharmacological strategies for treating alcohol use disorder.<\/div>\n<div aria-hidden=\"true\"><\/div>\n<\/section>\n<\/div>\n<div class=\"response-content ng-tns-c3460882200-47\">\n<div id=\"model-response-message-contentr_41146b6e5bee749e\" class=\"markdown markdown-main-panel stronger enable-updated-hr-color\" dir=\"ltr\">\n<p>Researchers from the U.S. National Institute on Alcohol Abuse and Alcoholism (NIAAA) analyzed extensive genetic data. They employed a method known as <b>Mendelian randomization<\/b> to investigate how genetic variations in the receptors for <b>Glucagon-like Peptide-1 (GLP1R)<\/b> and <b>Glucose-dependent Insulinotropic Polypeptide (GIPR)<\/b> influence alcohol-related behaviors.<\/p>\n<p>One intriguing finding of this study is that these genetic markers appear to be selective: they are associated only with alcohol consumption, showing <b>no connection<\/b> to other substances such as tobacco, cannabis, or opioids.<\/p>\n<p>However, a connection was found with dietary habits: individuals with the same genetic profile were more likely to choose <b>low-fat and plant-based foods<\/b>.<\/p>\n<p>This observation leads scientists to hypothesize that the processes of <b>metabolism<\/b> (how the body processes food) and <b>addiction<\/b> may share <b>common biological mechanisms<\/b>. In other words, the pathway our brain uses to regulate hunger might also be involved in managing alcohol craving.<\/p>\n<p>Although the study did not directly test GLP-1 and GIP-based drugs on individuals with alcohol use disorder, the data is compelling and suggests that weight loss medications could significantly reduce alcohol dependence.<\/p>\n<p>These findings lay a strong foundation for <b>future clinical trials<\/b> aimed at evaluating the therapeutic efficacy of <b>GLP-1 and GIP receptor agonists<\/b> in managing alcohol-related conditions. If confirmed, this approach could develop into a <b>novel dual-action strategy<\/b> that simultaneously addresses both the metabolic and addictive pathophysiological components of alcohol use disorder.<\/p>\n<p><a href=\"https:\/\/www.nature.com\/articles\/s41380-025-03199-3\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Nature<\/span><\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A recent, large-scale genetic study has revealed significant potential: medications already used to treat Type 2 Diabetes and obesity may also be effective in reducing alcohol consumption and, consequently, improving liver function. This research, published in the journal Molecular Psychiatry, points to the possibility of developing entirely new pharmacological strategies for treating alcohol use disorder. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7510,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1631,1594,1645,1587,1657],"tags":[2100],"class_list":["post-7511","post","type-post","status-publish","format-standard","has-post-thumbnail","category-neurology","category-news","category-psychiatry","category-research","category-science","tag-weight-loss-medications"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/7511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=7511"}],"version-history":[{"count":1,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/7511\/revisions"}],"predecessor-version":[{"id":7514,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/7511\/revisions\/7514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/7510"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=7511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=7511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=7511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}